Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor

Immune checkpoint inhibitors have shown anti-tumour activity in cancers such as melanoma, renal cell carcinoma, non-small-cell lung cancer, urothelial carcinoma, colorectal cancer, and Hodgkin’s lymphoma. Though immune checkpoint inhibitors have revolutionized the treatment and prognosis of some adv...

Full description

Bibliographic Details
Main Author: Rocha,Marta (author)
Other Authors: Sousa,João Correia de (author), Salgado,Marta (author), Araújo,António (author), Pedroto,Isabel (author)
Format: article
Language:eng
Published: 2019
Subjects:
Immune checkpoint inhibitor
Immune-related adverse event
Colitis
Diarrhoea
Online Access:http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452019000400007
Country:Portugal
Oai:oai:scielo:S2341-45452019000400007

Internet

http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452019000400007

Similar Items